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Dear Sirs,
Patients with visual snow (VS) describe tiny flickering dots
in the entire visual field often compared with the TV static in
case of a badly adjusted analog signal. It can be episodic with
migraine [1], but is debilitating when continuously present.
When occurring together with visual (palinopsia, enhanced
entoptic phenomena, photophobia, and nyctalopia) and a va-
riety of non-visual symptoms (tinnitus, concentration loss,
etc.), one speaks of visual snow syndrome (VSS) [2].
Pathophysiological mechanisms are still not well-under-
stood, and pharmacological treatment options are sparse. We
present a case of VSS onset after citalopram intake and discuss
this constellation in the light of “Hallucinogen Persisting
Perception Disorder” (HPPD) with possible shared receptor
mechanisms.
Case report
Two weeks after starting with citalopram 20 mg to treat post-
partum depression, a 31-year-old female developed visual dis-
turbances in terms of white and black dots in the entire visual
field, intermittent bright flashes, entoptic phenomena, swirls,
photophobia, and additionally increased irritability to external
sensory cues. Past medical history was unremarkable except
for episodic migraine without aura (every 8 weeks; MIDAS
0p). There was moderate anxiety and depression as assessed
by the GAD-7 anxiety scale (7p) and the PHQ-9 depression
scale (10p) at that time. There was no use of hallucinogenic
substances in the past. Diagnostics including thorough clinical
neurological and ophthalmological examination, visual
evoked potentials (16 k and 64 k), and MRI-scan of the brain
were unremarkable. VSS persisted after stopping citalopram.
An additionally used causality assessment tool (CAT) for ad-
verse drug reaction (ADR), namely the Liverpool ADR CAT,
indicated a possible adverse drug reaction [3].
Case discussion
Individual symptoms of VSS can overlap with conditions
such as visual migraine aura [2, 4] and HPPD [5, 6].
Particularly, VSS and HPPD symptoms largely overlap and
therefore might share common pathophysiological mecha-
nisms in terms of involved cerebral networks and changes in
synaptic transmission. The drug lysergic acid diethylamide
(LSD) mediates its hallucinogenic effects mainly via activat-
ing the serotonergic 5HT2a-receptor [7]. Even one-time con-
sumption of LSD can cause persistent HPPD with VS-like
symptoms [6]. Interestingly, there are reports on visual sensa-
tions arising years after LSD abuse triggered by the intake of
selective serotonin reuptake inhibitors (SSRI) in patients with
former HPPD [7]. Regarding our case, the hypothesis arises
that changes in serotonergic synaptic transmission, particular-
ly via 5HT2a-receptors, in primary and/or secondary visual
cortical areas might underlie VSS as well as HPPD.
Functional imaging studies revealed increased metabolism in
secondary visual cortical areas such as the lingual gyrus in
VSS [4]. There is evidence for a particularly high density of
5HT2-receptors of projections from the lateral geniculate body
of the thalamus to the primary visual cortex [8, 9]. It is hy-
pothesized that a shift in the balance of excitatory and inhib-
itory synaptic transmission in the visual cortex towards more
excitation due to a decrease in either the number or the func-
tional activation of inhibitory serotonergic interneurons might
play a crucial role in HPPD after LSD abuse [6]. Thus, in
subjects with an increased vulnerability, VSS might also be
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triggered by minor changes in serotonergic transmission due
to SSRI, like in our case. Further evidence for the important
role of serotonergic transmission derives from the at least par-
tial effectiveness of lamotrigine in both conditions [10–12], as
lamotrigine also has an inhibitory function on 5HT2a-recep-
tors [13].
Conclusion
This case report gives further insight for a possible role of
changes in serotonergic transmission in brain regions impor-
tant for visual processing as potentially underlying pathophys-
iological mechanism of VSS. Furthermore, common patho-
physiological changes in VSS and HPPD on the level of ce-
rebral network activations and synaptic transmission seem
plausible.
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